search
Back to results

Dorsal Genital Nerve Stimulation for Bladder Management After SCI (NEUROMOD UCon)

Primary Purpose

Spinal Cord Injuries, Neurogenic Bladder, Neurogenic Detrusor Overactivity

Status
Recruiting
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Neuromodulation
Sponsored by
University College, London
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional device feasibility trial for Spinal Cord Injuries

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Spinal Cord Injury (suprasacral, AIS A-D);
  • >18 years old, no upper age limit;
  • SCI sustained >6 months ago;
  • NDO;
  • Capable of using the device at home either independently or with existing support.
  • Male or female
  • Willing and able to provide informed consent

Exclusion Criteria:

  • recipient of intra-detrusor botulinum toxin injections within the last 6 months;
  • previous surgical intervention on bladder sphincters;
  • pregnancy;
  • cardiac pacemaker;
  • active sepsis;
  • history of significant autonomic dysreflexia;
  • poorly controlled epilepsy;
  • patients with a cancerous tumour in the area of electrical stimulation

Sites / Locations

  • Royal National Orthopaedic HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Treatment

Arm Description

Outcomes

Primary Outcome Measures

Change from baseline (week 1) in Maximum Cystometric capacity at post intervention (week 9) and follow up (week 13).
During standard cystometry (retrograde filling of the bladder), maximum cystometric capacity will be defined as the volume emptied from the bladder after each fill.

Secondary Outcome Measures

Maximum detrusor pressure
Maximum recorded detrusor pressure during standard cystometry (retrograde filling of the bladder).
3 day bladder diary (3DBD)
3DBDs will be completed on clinically used bladder diaries. Participants will record voided volumes, urinary and faecal incontinence episodes and daily spasticity for 3 days. This will involve measuring the volume voided each time they urinate over the three days, using provided measuring equipment.
Incontinence Quality of Life (I-QoL) Questionnaire
Validated questionnaire to measure incontinence related quality of life. Scoring is 0 to 100 with higher scores representing greater quality of life.
EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire
Validated questionnaire to measure general health. . Scoring is 0 to 100 with higher scores representing greater health
The Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST) Questionnaire
Validated questionnaire to measure acceptability of the UCon device. Scoring is 1 to 5 with higher scores representing greater acceptance.
VAS treatment satisfaction
Visual analogue scale to assess treatment satisfaction. Scoring is 0 to 10 with higher scores representing greater satisfaction
Semi structured interview
The research team will conduct a semi-structured interview with the participant to explore further their experience of using DGNS and gain any insights into its use and effects we were unable to obtain from study outcome measures.

Full Information

First Posted
August 9, 2022
Last Updated
January 23, 2023
Sponsor
University College, London
Collaborators
Royal National Orthopaedic Hospital NHS Trust
search

1. Study Identification

Unique Protocol Identification Number
NCT05502614
Brief Title
Dorsal Genital Nerve Stimulation for Bladder Management After SCI
Acronym
NEUROMOD UCon
Official Title
NEUROMOD UCon: Pilot Study of Dorsal Genital Nerve Stimulation for Management of Bladder Overactivity Following Spinal Cord Injury
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 23, 2023 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
December 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University College, London
Collaborators
Royal National Orthopaedic Hospital NHS Trust

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Following spinal cord injury signals between the brain and the bladder are disrupted. As a result the bladder often becomes overactive which can lead to the need for frequent trips to the toilet, regular incontinence episodes and a decreased quality-of-life. Neuromodulation is a therapy that aims to target the nerves that become overactive controlling the bladder, stopping the bladder overactivity on demand using an external (non-invasive) nerve stimulation box and sticker electrodes placed on the penis or clitoris. This study is a pilot study that aims to investigate neuromodulation for improving symptoms of bladder overactivity when used by 10 people over eight weeks at home. We will assess whether using the device improves bladder capacity, incontinence, frequency of needing the toilet and whether there are any longer lasting changes after 8 weeks. Finally, the study will aim to find out the acceptability of using this type of therapy for participants and the acceptability of the device we are using. Participants in this trial will participate over 13 weeks and need to visit our centre in Stanmore to have urodynamics tests in the 1st, 9th and 13th week. At home they will use a small stimulation device on a daily basis for 8 weeks to control overactivity in the bladder. Whilst at home they will record relevant outcomes in several three-day diaries and questionnaires. They will record baseline data before starting stimulation and for 4 weeks after.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Spinal Cord Injuries, Neurogenic Bladder, Neurogenic Detrusor Overactivity, Neurogenic Bladder Dysfunction

7. Study Design

Primary Purpose
Device Feasibility
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Treatment
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
Neuromodulation
Other Intervention Name(s)
Dorsal Genital Nerve Stimulation
Intervention Description
Transcutaneous stimulation of the dorsal genital nerve using the Innocon Medical UCon device to provide on demand relief of bladder spasms
Primary Outcome Measure Information:
Title
Change from baseline (week 1) in Maximum Cystometric capacity at post intervention (week 9) and follow up (week 13).
Description
During standard cystometry (retrograde filling of the bladder), maximum cystometric capacity will be defined as the volume emptied from the bladder after each fill.
Time Frame
Week 1, 9 and 13
Secondary Outcome Measure Information:
Title
Maximum detrusor pressure
Description
Maximum recorded detrusor pressure during standard cystometry (retrograde filling of the bladder).
Time Frame
Week 1, 9 and 13
Title
3 day bladder diary (3DBD)
Description
3DBDs will be completed on clinically used bladder diaries. Participants will record voided volumes, urinary and faecal incontinence episodes and daily spasticity for 3 days. This will involve measuring the volume voided each time they urinate over the three days, using provided measuring equipment.
Time Frame
Week 1, 2, 5, 9, 10 and 13
Title
Incontinence Quality of Life (I-QoL) Questionnaire
Description
Validated questionnaire to measure incontinence related quality of life. Scoring is 0 to 100 with higher scores representing greater quality of life.
Time Frame
Week 1, 5, 10 and 13
Title
EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire
Description
Validated questionnaire to measure general health. . Scoring is 0 to 100 with higher scores representing greater health
Time Frame
Week 1, 5, 10 and 13
Title
The Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST) Questionnaire
Description
Validated questionnaire to measure acceptability of the UCon device. Scoring is 1 to 5 with higher scores representing greater acceptance.
Time Frame
Week 10
Title
VAS treatment satisfaction
Description
Visual analogue scale to assess treatment satisfaction. Scoring is 0 to 10 with higher scores representing greater satisfaction
Time Frame
Week 10
Title
Semi structured interview
Description
The research team will conduct a semi-structured interview with the participant to explore further their experience of using DGNS and gain any insights into its use and effects we were unable to obtain from study outcome measures.
Time Frame
Week 10

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Spinal Cord Injury (suprasacral, AIS A-D); >18 years old, no upper age limit; SCI sustained >6 months ago; NDO; Capable of using the device at home either independently or with existing support. Male or female Willing and able to provide informed consent Exclusion Criteria: recipient of intra-detrusor botulinum toxin injections within the last 6 months; previous surgical intervention on bladder sphincters; pregnancy; cardiac pacemaker; active sepsis; history of significant autonomic dysreflexia; poorly controlled epilepsy; patients with a cancerous tumour in the area of electrical stimulation
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Lynsey Duffell, PhD
Phone
02083853787
Email
l.duffell@ucl.ac.uk
First Name & Middle Initial & Last Name or Official Title & Degree
Sean Doherty, PhD
Phone
02083853787
Email
sean.doherty.15@ucl.ac.uk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lynsey Duffell, PhD
Organizational Affiliation
University College, London
Official's Role
Principal Investigator
Facility Information:
Facility Name
Royal National Orthopaedic Hospital
City
Stanmore
State/Province
London
ZIP/Postal Code
HA7 4LP
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sarah Knight, PhD
Email
sarah.knight23@nhs.net

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
32355163
Citation
Doherty SP, Vanhoestenberghe A, Duffell LD, Hamid R, Knight SL. Ambulatory urodynamic monitoring assessment of dorsal genital nerve stimulation for suppression of involuntary detrusor contractions following spinal cord injury: a pilot study. Spinal Cord Ser Cases. 2020 Apr 30;6(1):30. doi: 10.1038/s41394-020-0279-4.
Results Reference
background

Learn more about this trial

Dorsal Genital Nerve Stimulation for Bladder Management After SCI

We'll reach out to this number within 24 hrs